Potential benefits of quetiapine in the treatment of substance dependence disorders

S. Pirzada Sattar, Subhash Bhatia, Frederick Petty

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Objective: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD. Methods: We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens. Results: Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use. Conclusion: Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety.

Original languageEnglish (US)
Pages (from-to)452-457
Number of pages6
JournalJournal of Psychiatry and Neuroscience
Volume29
Issue number6
StatePublished - Nov 1 2004

Fingerprint

Substance-Related Disorders
Anxiety
Alcohols
Therapeutics
Urine
Hypochondriasis
Pharmaceutical Preparations
Breath Tests
Methamphetamine
Quetiapine Fumarate
Sleep Initiation and Maintenance Disorders
Post-Traumatic Stress Disorders
Anxiety Disorders
Mood Disorders
Cocaine
Diagnostic and Statistical Manual of Mental Disorders
Psychotic Disorders
Antipsychotic Agents
Sleep
Rehabilitation

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this

Potential benefits of quetiapine in the treatment of substance dependence disorders. / Sattar, S. Pirzada; Bhatia, Subhash; Petty, Frederick.

In: Journal of Psychiatry and Neuroscience, Vol. 29, No. 6, 01.11.2004, p. 452-457.

Research output: Contribution to journalArticle

@article{0212ad54769a48e4928cdecec2918fce,
title = "Potential benefits of quetiapine in the treatment of substance dependence disorders",
abstract = "Objective: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD. Methods: We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens. Results: Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use. Conclusion: Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety.",
author = "Sattar, {S. Pirzada} and Subhash Bhatia and Frederick Petty",
year = "2004",
month = "11",
day = "1",
language = "English (US)",
volume = "29",
pages = "452--457",
journal = "Journal of Psychiatry and Neuroscience",
issn = "1180-4882",
publisher = "Canadian Medical Association",
number = "6",

}

TY - JOUR

T1 - Potential benefits of quetiapine in the treatment of substance dependence disorders

AU - Sattar, S. Pirzada

AU - Bhatia, Subhash

AU - Petty, Frederick

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Objective: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD. Methods: We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens. Results: Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use. Conclusion: Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety.

AB - Objective: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD. Methods: We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens. Results: Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use. Conclusion: Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety.

UR - http://www.scopus.com/inward/record.url?scp=11344260664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11344260664&partnerID=8YFLogxK

M3 - Article

C2 - 15644986

AN - SCOPUS:11344260664

VL - 29

SP - 452

EP - 457

JO - Journal of Psychiatry and Neuroscience

JF - Journal of Psychiatry and Neuroscience

SN - 1180-4882

IS - 6

ER -